Liver cancer is among the most common and malignant human cancers in the world. The incidence of liver cancer is increasing in the United States. The majority of liver cancers are developed over long period of time, often with chronic liver disease. This offers a window of opportunity to eradicate or at least slow the progression of liver cancer. The urgent issue is to identify molecular targets that can be used for early diagnosis and therapeutic intervention. Newly available aptamer and nanoparticle technology provides a unique opportunity for this purpose. In comparison with genomic and proteomic approaches, the aptamer technology can identify markers using intact tumor cells, which will have significant advantages by closely reflecting the physiological state of cancer. The overall objective of our research program is to apply this technology to select and characterize cancer-specific aptamers for human liver cancer early diagnosis and therapy. Our previous work has validated several cancer-specific aptamers, including murine liver cancer. We have established a reliable system to isolate and culture human primary hepatocytes and liver cancer cells. We have also validated an animal model for human liver cancer. In this proposal, we will generate and test human liver cancer-specific aptamers, and validate their application in cancer diagnosis and target therapy. The goal will be achieved through three specific aims:
Aim 1 : To identify and characterize human liver cancer cell-specific aptamers;
Aim 2. To apply aptamers and nanoparticles for human liver cancer diagnosis;
Aim 3. To develop novel and effective target cancer therapy using aptamers-nanoparticle-chemotherapy agent complexes. Our investigation will identify aptamers and biomarkers for liver caner in the context of intact cancer cells. The combination of aptamer and nanoparticles will provide a powerful tool for cancer early diagnosis and targeting therapy. The experience we gain will not only be instrumental for subsequent clinical trails but also have significant impact on biomarker discovery of other solid tumors.
Our proposal will address two of the most important issues in liver cancer management using novel aptamer/nanotechnology: discovery of effective molecular markers for early liver cancer diagnosis and validation of molecular markers for liver cancer therapy.
|Huang, Fujian; You, Mingxu; Chen, Tao et al. (2014) Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells. Chem Commun (Camb) 50:3103-5|
|Sefah, Kwame; Yang, Zunyi; Bradley, Kevin M et al. (2014) In vitro selection with artificial expanded genetic information systems. Proc Natl Acad Sci U S A 111:1449-54|
|Han, Da; Kang, Huaizhi; Zhang, Tao et al. (2014) Nucleic acid based logical systems. Chemistry 20:5866-73|
|You, Mingxu; Peng, Lu; Shao, Na et al. (2014) DNA "nano-claw": logic-based autonomous cancer targeting and therapy. J Am Chem Soc 136:1256-9|
|Sheng, Weian; Ogunwobi, Olorunseun O; Chen, Tao et al. (2014) Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip 14:89-98|
|Qiu, Liping; Zhang, Tao; Jiang, Jianhui et al. (2014) Cell membrane-anchored biosensors for real-time monitoring of the cellular microenvironment. J Am Chem Soc 136:13090-3|
|Wang, RuoWen; Wang, Chunming; Cao, Yang et al. (2014) Trifluoromethylated Nucleic Acid Analogues Capable of Self-Assembly through Hydrophobic Interactions. Chem Sci 5:4076-4081|
|Meng, Hong-Min; Zhang, Xiaobing; Lv, Yifan et al. (2014) DNA dendrimer: an efficient nanocarrier of functional nucleic acids for intracellular molecular sensing. ACS Nano 8:6171-81|
|Liang, Hao; Zhang, Xiao-Bing; Lv, Yifan et al. (2014) Functional DNA-containing nanomaterials: cellular applications in biosensing, imaging, and targeted therapy. Acc Chem Res 47:1891-901|
|Hu, Rong; Liu, Tao; Zhang, Xiao-Bing et al. (2014) Multicolor fluorescent biosensor for multiplexed detection of DNA. Anal Chem 86:5009-16|
Showing the most recent 10 out of 60 publications